

FILE COPY**K L A R Q U I S T S P A R K M A N , L L P**

Intellectual Property Legal Services • Including Patents, Trademarks, Copyrights & Litigation • Since 1941
One World Trade Center • 121 S.W. Salmon Street • Suite 1600 • Portland, Oregon 97204 • U.S.A.
Telephone: 503-226-7391 • www.klarquist.com
Facsimile: 503-228-9446

FAX TRANSMITTAL

DATE: June 13, 2002

TO: Attn: Filing Receipt OIPE

FAX PHONE: (703) 746-9195

FROM: Susan Alpert Siegel, Ph.D.

REGISTRATION NO. 43,121

RE: PTO Error in Filing Receipt Document

OUR FILE: 6203-61432

NO. PAGES 3 (including this cover page)

VIA FACSIMILE ONLY? Yes No

CONTACT INFO: If you do not receive all pages or if you have problems receiving transmittal, please call us at (503) 226-7391 as soon as possible and ask for Kim Nunez.

MESSAGE:

Applicants received accompanying Filing Receipt with an error in it (marked for easy reference). Please correct as listed on accompanying Filing Receipt.

cc: Docketing
Client

RECEIVED
DEC 04 2002
TECH CENTER 1600/2900

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

UNITED STATES PATENT AND TRADEMARK OFFICE


NMS
NIH / SAS
 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/068.160	02/06/2002	1623	1572	4239-61997	7	59	1

KLARQUIST SPARKMAN, LLP
 One World Trade Center
 Suite 1600
 121 S.W. Salmon Street
 Portland, OR 97204

~~PREVIOUSLY DOCKETED~~

CONFIRMATION NO. 9731
UPDATED FILING RECEIPT



DC000000008156048

Date Mailed: 05/20/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt Incorporating the requested corrections (if appropriate).

Applicant(s)

Dennis Klinman, Potomac, MD;
 Daniela Verthelyi, Potomac, MD;
 Ken Ishii, Rockville, MD;
 James J. Mond, Silver Spring, MD;
 Mayda Gursel, Rockville, MD;

Assignment For Published Patent Application

The Department of Health and Human Services,

The Government of the United States
 of America as represented by the
 Secretary of the Department of
 Health and Human Services

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/958,713
 WHICH CLAIMS BENEFIT OF 60/128,898 04/12/1999

Foreign Applications

If Required, Foreign Filing License Granted 03/11/2002

Projected Publication Date: 08/29/2002

Non-Publication Request: No

Early Publication Request: No

Title

Oligodeoxynucleotide and its us to induce an immune respons ✓

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).